In today’s increasingly regulated pharmacovigilance landscape, marketing-authorisation holders (MAHs) and pharmaceutical companies are under growing scrutiny to ensure that their third-party pharmacovigilance (PV) subcontractors comply fully with EU and global regulatory requirements. Regulatory authorities, including the European Medicines Agency (EMA) and the U.S. FDA, have emphasised that MAHs remain fully accountable for the activities of outsourced PV functions.
Failure to manage PV subcontractors effectively can result in audit findings, regulatory penalties, and reputational risks, particularly when agreements and oversight mechanisms are weak or ambiguous. To maintain compliance and prepare for inspections, organisations must ensure that vendor agreements are audit-ready, clearly define roles and responsibilities, and integrate robust quality and oversight provisions.
This blog explores the challenges associated with PV subcontractors, key considerations for audit-proofing vendor agreements, and best practices to safeguard compliance.
Why Third‑Party PV Subcontractors Are Under Increased Scrutiny
- MAH accountability does not transfer
Even when PV tasks are outsourced, MAHs are ultimately responsible for signal detection, adverse event reporting, and compliance with regulatory obligations. Regulatory inspectors often review subcontractor arrangements to verify that MAHs exercise appropriate oversight. - High risk of non-compliance
Third-party subcontractors may vary in their understanding of local regulations, SOP adherence, and quality standards. Any gaps can create audit triggers, delayed reporting, or mismanaged safety signals. - Increased regulatory audits
Recent EMA inspection trends show a rise in audits focused on subcontracted PV functions. Authorities examine agreements, SOP alignment, documentation, and corrective actions to ensure compliance is maintained throughout the outsourced workflow.
Key Elements to Include in Audit-Ready Vendor Agreements
1. Clear Definition of Roles and Responsibilities
- Clearly outline each party’s responsibilities for signal detection, case processing, and reporting.
- Specify who manages periodic safety update reports (PSURs), risk management plans (RMPs), and regulatory submissions.
A well-defined scope prevents ambiguity during audits and ensures that MAHs maintain oversight over all critical PV activities.
2. Regulatory Compliance Clauses
- Include clauses that require subcontractors to comply with global pharmacovigilance regulations, including EU GVP, FDA 21 CFR Part 11, and ICH E2E guidelines.
- Specify obligations for timely reporting, data privacy compliance, and inspection readiness.
Regulators expect subcontractors to meet the same standards as the MAH; these clauses formalise compliance requirements in legally binding agreements.
3. Audit and Inspection Rights
- Ensure contracts grant MAHs the right to audit subcontractors regularly.
- Include provisions for regulatory inspections that may involve subcontractor premises, documentation, and staff interviews.
Audit rights give MAHs the ability to verify compliance proactively and respond to regulatory scrutiny with evidence of oversight.
4. SOP Alignment and Document Control
- Require subcontractors to adhere to MAH SOPs or demonstrate equivalent processes.
- Include procedures for document version control, record retention, and reporting formats.
Alignment ensures that outsourced PV processes are consistent with organisational standards and reduces audit findings related to procedural gaps.
5. Risk Management and Corrective Actions
- Include contractual obligations for root cause analysis, CAPA (Corrective and Preventive Actions), and ongoing risk assessments.
- Ensure subcontractors report deviations or non-compliance promptly.
By embedding risk management obligations, agreements ensure that corrective actions are handled systematically and documented, strengthening audit readiness.
6. Data Privacy and Security Measures
- Include clauses addressing GDPR compliance, data encryption, and secure transmission of safety data.
- Define responsibilities for data storage, access control, and breach notifications.
Regulators increasingly evaluate how subcontractors protect sensitive patient data, making this a critical component of audit-proof agreements.
7. Performance Metrics and KPIs
- Specify key performance indicators (KPIs) such as case processing timelines, signal evaluation quality, and reporting accuracy.
- Include mechanisms for regular performance reviews and escalation pathways.
Monitoring subcontractor performance ensures operational efficiency and provides documented evidence for audits.
8. Termination and Escalation Clauses
- Define termination conditions if subcontractors fail to meet regulatory or contractual obligations.
- Include escalation procedures for non-compliance or repeated deviations.
Clear exit strategies protect MAHs and ensure that non-compliant subcontractors can be replaced without disrupting critical PV operations.
Best Practices to Ensure Vendor Agreements Remain Audit-Proof
- Regular contract reviews – Review and update agreements annually to reflect regulatory changes and organisational standards.
- Integrated oversight processes – Implement monitoring programmes that integrate audit findings, CAPA follow-up, and performance KPIs.
- Documentation of all communications – Maintain thorough records of subcontractor interactions, deviations, and corrective actions.
- Training and competency verification – Ensure subcontractor personnel are trained on regulatory expectations and MAH-specific SOPs.
- Leverage technology – Use electronic PV systems for case management, audit trails, and reporting metrics that are accessible for inspection.
These practices not only mitigate regulatory risk but also improve efficiency and strengthen vendor relationships.
Preparing for Regulatory Inspections
Regulators often focus on third-party subcontractors during PV audits. To prepare:
- Conduct mock audits of subcontractors to identify gaps before inspection.
- Ensure SOPs, contracts, and CAPA documentation are consistent, complete, and traceable.
- Train internal teams on inspection procedures, including review of vendor agreements and oversight documentation.
- Maintain a central repository of subcontractor documentation to enable rapid retrieval during inspections.
Proactive preparation reduces the risk of audit findings and ensures regulators recognise the MAH’s effective oversight.
The Role of Quality and Vigilance Ltd in Audit-Proofing PV Subcontractors
Navigating the complex regulatory landscape and ensuring that third-party PV subcontractors comply with evolving standards can be challenging. Quality and Vigilance Ltd provides end-to-end support to help organisations audit-proof vendor agreements and maintain regulatory compliance. Services include:
- Vendor contract review and optimisation – Ensure agreements cover all regulatory, audit, and performance requirements.
- SOP alignment and process integration – Support subcontractors to adopt MAH SOPs and document control standards.
- Audit readiness and inspection preparation – Conduct mock audits, identify gaps, and implement CAPA processes.
- Training and competency programmes – Equip internal teams and subcontractor personnel with the knowledge to meet regulatory expectations.
- Ongoing compliance monitoring – Provide continuous oversight to ensure subcontractor performance, risk management, and reporting remain audit-ready.
Partnering with Quality and Vigilance Ltd allows organisations to reduce compliance risk, streamline subcontractor oversight, and demonstrate regulatory accountability confidently during inspections.
Strengthening Compliance Through Robust Vendor Management
Third-party PV subcontractors are increasingly in the regulatory spotlight. Organisations that proactively audit-proof their vendor agreements ensure clear accountability, robust SOP alignment, and demonstrable oversight. By combining comprehensive contracts, performance monitoring, risk management, and expert support from partners like Quality and Vigilance Ltd, companies can maintain compliance, reduce regulatory risk, and safeguard patient safety.
Strong vendor agreements are not just legal documents they are essential tools for operational resilience, audit readiness, and regulatory confidence in today’s pharmacovigilance environment.